Soleno Therapeutics Presents New VYKAT® XR (diazoxide choline) Data at ENDO 2026 Demonstrating Meaningful and Durable Improvements in Hyperphagia and Behavioral Symptoms in Prader-Willi Syndrome Following Randomized Withdrawal Period
Neurocrine Biosciences presented late-breaking Phase 3 data for VYKAT XR at ENDO 2026, demonstrating durable improvements in hyperphagia and behavioral symptoms in Prader-Willi syndrome patients. Patients who resumed treatment after a 16-week placebo withdrawal showed significant recovery of benefit, with HQ-CT scores improving by 6.3 points at two years, while continuous users maintained stable improvements.
Key figures
- Drug Name
- VYKAT XR (diazoxide choline)
- Phase Of Trial
- Phase 3
- Mean age
- 15.3
- Female percentage
- 55.8%
- Study participants
- 77
- Path participants control
- 229
- Path participants treated
- 125
- Path comparison year1 diff
- 6.2
- Path comparison year2 diff
- 6.5
- Path comparison year3 diff
- 6.2
- Hq ct improvement restart 2yr
- -6.3
- Hq ct improvement continuous 2yr
- -3.1
- Hq ct improvement restart week13
- -4.5
- Hq ct improvement continuous week13
- -2.7
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.